Total Funding
20
37
Total FundingPost-IPO Equity raised
Growth Score
-6 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
82163
CureVac develops mRNA-based therapies for medical applications, including cancer treatment.
- Florian von der Mulbe: Co-Founder, CPOPast Role: University of Tuebingen, Prof. Jung
- Ulrike Gnad-Vogt: Chief Medical OfficerPast Role: Heidelberg University, U.S., Senior House Officer
About the Company
CureVac develops messenger RNA (mRNA) technology for a variety of medical applications. The company focuses on creating innovative therapies aimed at treating diseases, particularly in the field of oncology. CureVac's pipeline includes mRNA-based vaccines and treatments that target various types of cancer, enhancing the body's immune
response. Additionally, the company explores mRNA applications for infectious diseases, aiming to provide solutions that address public health challenges. Through its research and development efforts, CureVac contributes to the advancement of mRNA as a transformative approach in medicine.
